Shuttle Pharmaceuticals Holdings, Inc. (SHPH) - 10-K Summary
Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Reporting Period: Fiscal year ended December 31, 2024
Business Model: Clinical-stage pharmaceutical company developing novel radiation sensitizers and immune response regulators to enhance cancer treatments (specifically radiation therapy).
Key Assets: Lead candidate Ropidoxuridine (IPdR) for glioblastoma; HDAC inhibitor platform (SP-2-225, SP-1-303); and diagnostic assets (PC-RAD Test, PSMA-B ligand).
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9,144,797) | $(6,592,723) |
| Operating Expenses | $7,696,170 | $5,892,382 |
| Research & Development | $3,618,796 | $3,517,093 |
| Legal & Professional | $2,684,665 | $1,328,435 |
| Cash & Equivalents (End of Period) | $1,920,144 | $2,576,416 |
| Working Capital | $677,148 | $4,550,768 |
| Stockholders' Equity | $709,152 | $4,055,771 |
Note: The company has no product sales revenue. Expenses are driven by clinical trials and regulatory compliance.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 39% ($2.55 million) primarily due to higher operating expenses and other expenses.
- Legal & Professional Fees: Doubled (102% increase) to $2.68 million, driven by costs associated with the restatement of prior financial periods and public filing requirements.
- Other Expenses: Increased 107% to $1.45 million, largely due to a $0.83 million loss on the settlement of convertible debt and changes in fair value of derivative liabilities.
- Working Capital Decline: Working capital decreased by 85% to $0.68 million due to cash burn from R&D and filing expenses.
- Financing Activity: Completed an October 2024 equity raise (net proceeds ~$4.0 million) and a senior secured convertible note offering (net proceeds ~$0.68 million) to fund operations.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Progress: Commenced Phase II clinical trial for Ropidoxuridine in glioblastoma patients. As of February 24, 2025, 17 patients had enrolled, with half completing treatment. The FDA recommended an expansion of the trial to include dose optimization.
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. Existing cash resources are insufficient to fund operations for the next 12 months without additional financing.
- Nasdaq Compliance Risks:
- Minimum Bid Price: Received notice of non-compliance (price below $1.00) on Dec 31, 2024. Has 180 days (until June 30, 2025) to regain compliance.
- Stockholders' Equity: Received notice of non-compliance (equity below $2.5 million) on Sept 10, 2024. Granted extension until March 10, 2025, to regain compliance via equity raise.
- Financial Restatement: The company restated financial statements for 2022, 2023, and Q1 2024 following a re-audit. This led to the identification of material weaknesses in internal controls over financial reporting.
- Internal Controls: Management concluded disclosure controls and procedures were ineffective as of December 31, 2024, citing weaknesses in segregation of duties, IT general controls, and accounting for complex transactions.
Investor Verification Checklist
- Capital Runway: Verify the status of the planned follow-on equity offering intended to meet the March 10, 2025 Nasdaq equity compliance deadline.
- Phase II Trial Enrollment: Confirm current patient enrollment rates and whether the expanded trial scope (dose optimization) is proceeding as planned.
- Internal Control Remediation: Review progress on remediation of material weaknesses in internal controls, specifically regarding segregation of duties and complex debt/equity accounting.
- Debt Obligations: Assess the terms and repayment schedule of the new senior secured convertible notes issued in October 2024.
- Nasdaq Delisting Risk: Monitor stock price performance to ensure compliance with the $1.00 minimum bid price requirement by June 30, 2025.